{"success":true,"data":{"pressRelease":{"id":"88631","rtpr_id":"nBw9zd4S7a","ticker":"ALNY","exchange":"NASDAQ","all_tickers":["ALNY"],"title":"Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease","author":"Business Wire","published_at":"2026-07-15T07:30:00.069Z","article_body":"Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026,\nShowcasing Potential of RNAi in Neurological Disease\n\n− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down\nSyndrome–Associated Alzheimer’s Disease (DS-AD) −\n\n− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of\nMivelsiran in Cerebral Amyloid Angiopathy (CAA) −\n\n− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s\nDisease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities\n(ARIA) −\n\n− Shares Preclinical Data and Design of Ongoing Phase 1 Study of\nTau-Targeting ALN‑5288 in Alzheimer’s Patients –\n\nAlnylam Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2F&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=Alnylam+Pharmaceuticals%2C+Inc.&index=1&md5=e48d640b1f5d158f1373f212de2050b2)\n(Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances\nacross its growing neuroscience portfolio at the Alzheimer’s Association\nInternational Conference (AAIC) 2026. This scientific progress underscores the\npotential of RNAi therapeutics to address the needs of patients with\ndebilitating neurological diseases.\n\nMivelsiran: An investigational RNAi therapeutic targeting amyloid precursor\nprotein (APP) in development for Cerebral Amyloid Angiopathy (CAA) and\nAlzheimer’s disease (AD)\n\nThe company announced the initiation of a Phase 2 study of mivelsiran in\npeople with Down syndrome-associated AD and presented a poster detailing the\ndesign and rationale. The APPlauDS Study (evaluating APP-lowering to reduce\namyloid accumulation in Down syndrome) will be recruiting people with Down\nsyndrome with early-stage AD across approximately 30 global sites.\n\n“People with Down syndrome have a genetically determined form of\nAlzheimer’s disease that is now the leading cause of death among adults over\nage 35 years,” said Michael S. Rafii, M.D., Ph.D., Professor of Neurology at\nthe Keck School of Medicine of USC and presenting author. “APPlauDS is the\nfirst clinical trial to evaluate whether an RNAi approach can reduce APP\noverexpression caused by trisomy 21, where the APP gene is located. By\nlowering APP expression early in the disease process, this approach has the\npotential to slow or prevent the progression of Alzheimer’s disease in\npeople with Down syndrome.”\n\nAn additional presentation included updated data from the Phase 1 trial of\nmivelsiran in patients with early-onset Alzheimer’s disease. An analysis of\nsafety data from single- and multiple-doses of mivelsiran showed no evidence\nof increased risk of amyloid-related imaging abnormality (ARIA) events.\nResults also showed robust, durable reductions in cerebrospinal fluid (CSF)\nsoluble amyloid beta precursor protein (sAPPβ) and amyloid beta 42 (Aβ42),\nwith up to 30 months of treatment exposure. The mean maximum reductions in the\nhighest dose group were -89.9% and -70.2% change from baseline for sAPPβ and\nAβ42, respectively. The most common adverse events (AEs) were procedural pain\nand procedural headache, and no serious or severe AEs were deemed related to\nstudy drug. CSF safety labs showed no significant elevations of CSF total\nprotein or white blood cells.\n\nAlnylam also announced today that it has completed enrollment in the Phase 2\ncAPPricorn-1 study of mivelsiran in CAA, a leading cause of hemorrhagic\nstroke. CAA is defined by progressive deposition of Aβ in blood vessels of\nthe brain. Reducing APP production reduces downstream Aβ accumulation and\ncould potentially slow CAA progression and CAA-related bleeds in the brain.\ncAPPricorn-1’s primary endpoint is rate of new lobar microbleeds measured by\nmagnetic resonance imaging (MRI) with initial results expected in 2028.\n\nALN-5288: An investigational RNAi therapeutic targeting Microtubule-Associated\nProtein Tau (MAPT) in development for Alzheimer’s disease and tauopathies\n\nAlnylam also highlighted progress with ALN-5288 – an investigational asset\nin development in collaboration with Regeneron Pharmaceuticals – in\npresentations of preclinical data and of the design of the ongoing\nfirst-in-human Phase 1 trial (NCT07214727), which initiated in the fourth\nquarter of 2025.\n\nWith mivelsiran and ALN-5288, Alnylam has two RNAi therapeutics targeting AD\nin clinical development, and, together with its collaboration partner\nRegeneron, a total of seven clinical programs\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2Falnylam-rnai-pipeline&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=seven+clinical+programs&index=2&md5=15f1126779dd9fa7f069dd1a491e01d9)\nfor neuroscience indications.\n\n“The updates we’re sharing at AAIC 2026 mark an important step forward for\nAlnylam as we continue to build our leadership in neuroscience,” said Toby\nFerguson, M.D., Ph.D., Senior Vice President and Head of the Neuroscience\nTherapeutic Area at Alnylam. “Our RNAi platform is demonstrating strong\npotential across neurological diseases, with a favorable safety profile and\nthe possibility to reach broad patient populations. By targeting\ndisease-driving proteins like amyloid and tau at their genetic source, we aim\nto deliver the kind of transformative, disease-modifying therapies patients\nand families have long awaited.”\n\nTo view Alnylam’s AAIC 2026 presentations please visit Capella\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcapella.alnylam.com%2Four-science%2Fcapella-rnai-innovation&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=Capella&index=3&md5=76bec2c7af2942a0c04a745cdf301129)\n.\n\nAbout RNAi\n\nRNAi (RNA interference) is a natural cellular process of gene silencing that\nrepresents one of the most promising and rapidly advancing frontiers in\nbiology and drug development today. Its discovery has been heralded as “a\nmajor scientific breakthrough that happens once every decade or so” and was\nrecognized with the award of the 2006 Nobel Prize for Physiology or Medicine.\nBy harnessing the natural biological process of RNAi occurring in our cells, a\nnew class of medicines known as RNAi therapeutics is now a reality. Small\ninterfering RNA (siRNA), the molecules that mediate RNAi and comprise\nAlnylam’s RNAi therapeutic platform, function upstream of today’s\nmedicines by potently silencing messenger RNA (mRNA) – the genetic\nprecursors – that encode for disease-causing or disease pathway proteins,\nthus preventing them from being made. This is a revolutionary approach with\nthe potential to transform the care of patients with genetic and other\ndiseases.\n\nAbout Alzheimer’s Disease\n\nAlzheimer’s disease (AD) is the most common neurodegenerative disease and\nthe most common form of dementia, affecting over 30 million people worldwide.\nAmyloid and tau are widely viewed as the two principal biological drivers of\nAD, together contributing to the cascade of neurodegeneration and cognitive\ndecline. Disease progression results in progressive loss of independence,\nincreased caregiver burden, institutionalization and premature death.\nEarly-onset Alzheimer’s disease (EOAD), the leading cause of dementia in\nyounger individuals, refers to a subgroup of AD with symptom onset prior to\nthe age of 65, representing approximately 4% to 6% of all AD. People with Down\nsyndrome (DS) have a near-complete risk of developing Alzheimer’s disease\n(AD) in late adulthood; AD has become the leading cause of death in adults\nwith DS. DS-AD is caused by overexpression of amyloid precursor protein (APP)\ndue to an additional copy of chromosome 21 (Trisomy 21), the locus of the APP\ngene.\n\nAbout Cerebral Amyloid Angiopathy\n\nCerebral amyloid angiopathy (CAA) is the second most-common cause of\nhemorrhagic stroke. CAA is defined by progressive deposition of amyloid beta\n(Aβ) into the walls of small arteries, arterioles and capillaries in the\nbrain, causing impaired vascular reactivity, focal tissue damage and increased\nrisk for intracerebral hemorrhage. CAA has also been shown to be an\nindependent contributor to cognitive impairment. There are currently no\navailable treatment options for CAA.\n\nAbout Alnylam Pharmaceuticals\n\nAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the\npioneer of the RNA interference (RNAi) revolution. The Company is focused on\ndeveloping transformative therapies with the potential to prevent, halt or\nreverse disease. For more than two decades, Alnylam has advanced the\nNobel-Prize-winning science of RNAi, delivering critical breakthroughs and six\napproved medicines. Alnylam has medicines available in more than 70 countries\nand a rapidly expanding and robust pipeline, in addition to consistently being\nrecognized as an exceptional workplace and socially responsible organization.\nThe Company is executing on its Alnylam 2030 strategy to accelerate innovation\nand scale impact to transform human health.\n\nAlnylam Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. All statements other than historical statements of fact\nregarding Alnylam’s expectations, beliefs, goals, plans or prospects,\nincluding, without limitation, statements regarding the potential of RNAi\ntherapeutics to address the needs of patients with neurological diseases; the\npotential efficacy or safety of any of Alnylam’s product candidates; the\npotential for mivelsiran to slow or prevent the progression of Alzheimer’s\ndisease in people with Down syndrome; the timing of the publication of results\nfrom any of Alnylam’s clinical trials; the potential for Alnylam’s RNAi\nplatform to treat neurological diseases with a favorable safety profile and\nthe possibility to reach broad patient populations; Alnylam’s ability to\ndeliver transformative, disease-modifying therapies patients and families have\nlong awaited; and Alnylam’s ability to execute on its Alnylam 2030 strategy\nto accelerate innovation and scale to transform human health, should be\nconsidered forward-looking statements. Actual results and future plans may\ndiffer materially from those indicated by these forward-looking statements as\na result of various important risks, uncertainties and other factors,\nincluding, without limitation, risks and uncertainties relating to:\nAlnylam’s ability to successfully execute on its “Alnylam 2030”\nstrategy; Alnylam’s ability to successfully launch, market and sell\nAlnylam’s approved products globally; Alnylam’s ability to discover and\ndevelop novel drug candidates and delivery approaches and successfully\ndemonstrate the efficacy and safety of its product candidates; the\npre-clinical and clinical results for Alnylam’s product candidates; actions\nor advice of regulatory agencies and Alnylam’s ability to obtain and\nmaintain regulatory approval for its product candidates, as well as favorable\npricing and reimbursement; delays, interruptions or failures in the\nmanufacture and supply of Alnylam’s marketed products or its product\ncandidates; obtaining, maintaining and protecting intellectual property;\nAlnylam’s ability to manage its growth and operating expenses through\ndisciplined investment in operations; Alnylam’s ability to maintain\nstrategic business collaborations; Alnylam’s dependence on third parties for\nthe development and commercialization of certain products; the outcome of\nlitigation and government investigations; the risk of future litigation and\ngovernment investigations; and unexpected expenditures; as well as those risks\nand uncertainties more fully discussed in the “Risk Factors” filed with\nAlnylam’s 2025 Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC), as may be updated from time to time in Alnylam’s\nsubsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam\nmakes with the SEC. In addition, any forward-looking statements represent\nAlnylam’s views only as of today and should not be relied upon as\nrepresenting its views as of any subsequent date. Alnylam explicitly disclaims\nany obligation, except to the extent required by law, to update any\nforward-looking statements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260715865310/en/\n(https://www.businesswire.com/news/home/20260715865310/en/)\n\nAlnylam Pharmaceuticals, Inc. \n\nBo Piela\n\n(Media)\n\n508-308-9783\n\n\n\nJosh Brodsky\n\n(Investors)\n\n617-551-8276\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9zd4S7a","title":"Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease","author":"Business Wire","ticker":"ALNY","created":"2026-07-15T07:30:00.069Z","tickers":["ALNY"],"exchange":"NASDAQ","article_body":"Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026,\nShowcasing Potential of RNAi in Neurological Disease\n\n− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down\nSyndrome–Associated Alzheimer’s Disease (DS-AD) −\n\n− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of\nMivelsiran in Cerebral Amyloid Angiopathy (CAA) −\n\n− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s\nDisease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities\n(ARIA) −\n\n− Shares Preclinical Data and Design of Ongoing Phase 1 Study of\nTau-Targeting ALN‑5288 in Alzheimer’s Patients –\n\nAlnylam Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2F&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=Alnylam+Pharmaceuticals%2C+Inc.&index=1&md5=e48d640b1f5d158f1373f212de2050b2)\n(Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances\nacross its growing neuroscience portfolio at the Alzheimer’s Association\nInternational Conference (AAIC) 2026. This scientific progress underscores the\npotential of RNAi therapeutics to address the needs of patients with\ndebilitating neurological diseases.\n\nMivelsiran: An investigational RNAi therapeutic targeting amyloid precursor\nprotein (APP) in development for Cerebral Amyloid Angiopathy (CAA) and\nAlzheimer’s disease (AD)\n\nThe company announced the initiation of a Phase 2 study of mivelsiran in\npeople with Down syndrome-associated AD and presented a poster detailing the\ndesign and rationale. The APPlauDS Study (evaluating APP-lowering to reduce\namyloid accumulation in Down syndrome) will be recruiting people with Down\nsyndrome with early-stage AD across approximately 30 global sites.\n\n“People with Down syndrome have a genetically determined form of\nAlzheimer’s disease that is now the leading cause of death among adults over\nage 35 years,” said Michael S. Rafii, M.D., Ph.D., Professor of Neurology at\nthe Keck School of Medicine of USC and presenting author. “APPlauDS is the\nfirst clinical trial to evaluate whether an RNAi approach can reduce APP\noverexpression caused by trisomy 21, where the APP gene is located. By\nlowering APP expression early in the disease process, this approach has the\npotential to slow or prevent the progression of Alzheimer’s disease in\npeople with Down syndrome.”\n\nAn additional presentation included updated data from the Phase 1 trial of\nmivelsiran in patients with early-onset Alzheimer’s disease. An analysis of\nsafety data from single- and multiple-doses of mivelsiran showed no evidence\nof increased risk of amyloid-related imaging abnormality (ARIA) events.\nResults also showed robust, durable reductions in cerebrospinal fluid (CSF)\nsoluble amyloid beta precursor protein (sAPPβ) and amyloid beta 42 (Aβ42),\nwith up to 30 months of treatment exposure. The mean maximum reductions in the\nhighest dose group were -89.9% and -70.2% change from baseline for sAPPβ and\nAβ42, respectively. The most common adverse events (AEs) were procedural pain\nand procedural headache, and no serious or severe AEs were deemed related to\nstudy drug. CSF safety labs showed no significant elevations of CSF total\nprotein or white blood cells.\n\nAlnylam also announced today that it has completed enrollment in the Phase 2\ncAPPricorn-1 study of mivelsiran in CAA, a leading cause of hemorrhagic\nstroke. CAA is defined by progressive deposition of Aβ in blood vessels of\nthe brain. Reducing APP production reduces downstream Aβ accumulation and\ncould potentially slow CAA progression and CAA-related bleeds in the brain.\ncAPPricorn-1’s primary endpoint is rate of new lobar microbleeds measured by\nmagnetic resonance imaging (MRI) with initial results expected in 2028.\n\nALN-5288: An investigational RNAi therapeutic targeting Microtubule-Associated\nProtein Tau (MAPT) in development for Alzheimer’s disease and tauopathies\n\nAlnylam also highlighted progress with ALN-5288 – an investigational asset\nin development in collaboration with Regeneron Pharmaceuticals – in\npresentations of preclinical data and of the design of the ongoing\nfirst-in-human Phase 1 trial (NCT07214727), which initiated in the fourth\nquarter of 2025.\n\nWith mivelsiran and ALN-5288, Alnylam has two RNAi therapeutics targeting AD\nin clinical development, and, together with its collaboration partner\nRegeneron, a total of seven clinical programs\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.alnylam.com%2Falnylam-rnai-pipeline&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=seven+clinical+programs&index=2&md5=15f1126779dd9fa7f069dd1a491e01d9)\nfor neuroscience indications.\n\n“The updates we’re sharing at AAIC 2026 mark an important step forward for\nAlnylam as we continue to build our leadership in neuroscience,” said Toby\nFerguson, M.D., Ph.D., Senior Vice President and Head of the Neuroscience\nTherapeutic Area at Alnylam. “Our RNAi platform is demonstrating strong\npotential across neurological diseases, with a favorable safety profile and\nthe possibility to reach broad patient populations. By targeting\ndisease-driving proteins like amyloid and tau at their genetic source, we aim\nto deliver the kind of transformative, disease-modifying therapies patients\nand families have long awaited.”\n\nTo view Alnylam’s AAIC 2026 presentations please visit Capella\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcapella.alnylam.com%2Four-science%2Fcapella-rnai-innovation&esheet=54570009&newsitemid=20260715865310&lan=en-US&anchor=Capella&index=3&md5=76bec2c7af2942a0c04a745cdf301129)\n.\n\nAbout RNAi\n\nRNAi (RNA interference) is a natural cellular process of gene silencing that\nrepresents one of the most promising and rapidly advancing frontiers in\nbiology and drug development today. Its discovery has been heralded as “a\nmajor scientific breakthrough that happens once every decade or so” and was\nrecognized with the award of the 2006 Nobel Prize for Physiology or Medicine.\nBy harnessing the natural biological process of RNAi occurring in our cells, a\nnew class of medicines known as RNAi therapeutics is now a reality. Small\ninterfering RNA (siRNA), the molecules that mediate RNAi and comprise\nAlnylam’s RNAi therapeutic platform, function upstream of today’s\nmedicines by potently silencing messenger RNA (mRNA) – the genetic\nprecursors – that encode for disease-causing or disease pathway proteins,\nthus preventing them from being made. This is a revolutionary approach with\nthe potential to transform the care of patients with genetic and other\ndiseases.\n\nAbout Alzheimer’s Disease\n\nAlzheimer’s disease (AD) is the most common neurodegenerative disease and\nthe most common form of dementia, affecting over 30 million people worldwide.\nAmyloid and tau are widely viewed as the two principal biological drivers of\nAD, together contributing to the cascade of neurodegeneration and cognitive\ndecline. Disease progression results in progressive loss of independence,\nincreased caregiver burden, institutionalization and premature death.\nEarly-onset Alzheimer’s disease (EOAD), the leading cause of dementia in\nyounger individuals, refers to a subgroup of AD with symptom onset prior to\nthe age of 65, representing approximately 4% to 6% of all AD. People with Down\nsyndrome (DS) have a near-complete risk of developing Alzheimer’s disease\n(AD) in late adulthood; AD has become the leading cause of death in adults\nwith DS. DS-AD is caused by overexpression of amyloid precursor protein (APP)\ndue to an additional copy of chromosome 21 (Trisomy 21), the locus of the APP\ngene.\n\nAbout Cerebral Amyloid Angiopathy\n\nCerebral amyloid angiopathy (CAA) is the second most-common cause of\nhemorrhagic stroke. CAA is defined by progressive deposition of amyloid beta\n(Aβ) into the walls of small arteries, arterioles and capillaries in the\nbrain, causing impaired vascular reactivity, focal tissue damage and increased\nrisk for intracerebral hemorrhage. CAA has also been shown to be an\nindependent contributor to cognitive impairment. There are currently no\navailable treatment options for CAA.\n\nAbout Alnylam Pharmaceuticals\n\nAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the\npioneer of the RNA interference (RNAi) revolution. The Company is focused on\ndeveloping transformative therapies with the potential to prevent, halt or\nreverse disease. For more than two decades, Alnylam has advanced the\nNobel-Prize-winning science of RNAi, delivering critical breakthroughs and six\napproved medicines. Alnylam has medicines available in more than 70 countries\nand a rapidly expanding and robust pipeline, in addition to consistently being\nrecognized as an exceptional workplace and socially responsible organization.\nThe Company is executing on its Alnylam 2030 strategy to accelerate innovation\nand scale impact to transform human health.\n\nAlnylam Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934. All statements other than historical statements of fact\nregarding Alnylam’s expectations, beliefs, goals, plans or prospects,\nincluding, without limitation, statements regarding the potential of RNAi\ntherapeutics to address the needs of patients with neurological diseases; the\npotential efficacy or safety of any of Alnylam’s product candidates; the\npotential for mivelsiran to slow or prevent the progression of Alzheimer’s\ndisease in people with Down syndrome; the timing of the publication of results\nfrom any of Alnylam’s clinical trials; the potential for Alnylam’s RNAi\nplatform to treat neurological diseases with a favorable safety profile and\nthe possibility to reach broad patient populations; Alnylam’s ability to\ndeliver transformative, disease-modifying therapies patients and families have\nlong awaited; and Alnylam’s ability to execute on its Alnylam 2030 strategy\nto accelerate innovation and scale to transform human health, should be\nconsidered forward-looking statements. Actual results and future plans may\ndiffer materially from those indicated by these forward-looking statements as\na result of various important risks, uncertainties and other factors,\nincluding, without limitation, risks and uncertainties relating to:\nAlnylam’s ability to successfully execute on its “Alnylam 2030”\nstrategy; Alnylam’s ability to successfully launch, market and sell\nAlnylam’s approved products globally; Alnylam’s ability to discover and\ndevelop novel drug candidates and delivery approaches and successfully\ndemonstrate the efficacy and safety of its product candidates; the\npre-clinical and clinical results for Alnylam’s product candidates; actions\nor advice of regulatory agencies and Alnylam’s ability to obtain and\nmaintain regulatory approval for its product candidates, as well as favorable\npricing and reimbursement; delays, interruptions or failures in the\nmanufacture and supply of Alnylam’s marketed products or its product\ncandidates; obtaining, maintaining and protecting intellectual property;\nAlnylam’s ability to manage its growth and operating expenses through\ndisciplined investment in operations; Alnylam’s ability to maintain\nstrategic business collaborations; Alnylam’s dependence on third parties for\nthe development and commercialization of certain products; the outcome of\nlitigation and government investigations; the risk of future litigation and\ngovernment investigations; and unexpected expenditures; as well as those risks\nand uncertainties more fully discussed in the “Risk Factors” filed with\nAlnylam’s 2025 Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC), as may be updated from time to time in Alnylam’s\nsubsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam\nmakes with the SEC. In addition, any forward-looking statements represent\nAlnylam’s views only as of today and should not be relied upon as\nrepresenting its views as of any subsequent date. Alnylam explicitly disclaims\nany obligation, except to the extent required by law, to update any\nforward-looking statements.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260715865310/en/\n(https://www.businesswire.com/news/home/20260715865310/en/)\n\nAlnylam Pharmaceuticals, Inc. \n\nBo Piela\n\n(Media)\n\n508-308-9783\n\n\n\nJosh Brodsky\n\n(Investors)\n\n617-551-8276\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-15T07:30:00.136713272Z","server_sent_at_ms":1784100600136},"received_at":"2026-07-15T07:30:00.203Z","source_url":"https://www.businesswire.com/news/home/20260715865310/en/"},"analysis":{"id":"77687","press_release_id":"88631","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Alnylam presented updated Phase 1 data for Mivelsiran in early-onset Alzheimer’s disease, showing robust biomarker reductions of up to 90% with no evidence of increased ARIA risk.\n\nThe company initiated a global Phase 2 study for Down Syndrome-associated Alzheimer’s and completed enrollment in a Phase 2 study for Cerebral Amyloid Angiopathy.\n\nAdditionally, Alnylam shared preclinical data and design for the tau-targeting ALN-5288, an asset being developed in collaboration with Regeneron.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Mivelsiran shows 90% biomarker reduction without ARIA, clearing a major safety hurdle in Alzheimer's development."},"keyFigures":{"drugName":"Mivelsiran","phaseOfTrial":"Phase 1 and Phase 2","customDimensions":{"global_sites":30,"A_beta_42_reduction":"-70.2%","sAPP_beta_reduction":"-89.9%","treatment_exposure_months":30}},"quotedText":"Our RNAi platform is demonstrating strong potential across neurological diseases, with a favorable safety profile and the possibility to reach broad patient populations.","namedEntities":{"people":[{"name":"Toby Ferguson","role":"Senior Vice President and Head of the Neuroscience Therapeutic Area"},{"name":"Michael S. Rafii","role":"Professor of Neurology at the Keck School of Medicine of USC"}],"products":["Mivelsiran","ALN-5288"],"companies":[{"name":"Alnylam Pharmaceuticals, Inc.","ticker":"ALNY"},{"name":"Regeneron Pharmaceuticals","relationship":"collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Phase 1 data shows robust biomarker reduction without ARIA risk—a key competitive differentiator in Alzheimer's—while Phase 2 programs are advancing or fully enrolled."},"tickerRelevance":{"others":[],"primary":"ALNY"},"globalImportance":35,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-large-cap","diseaseArea":"Alzheimer's / Neuroscience","eventGravity":"Phase 1/2 clinical milestones","sectorWeight":"Biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Alnylam presented updated Phase 1 data for Mivelsiran in early-onset Alzheimer’s disease, showing robust biomarker reductions of up to 90% with no evidence of increased ARIA risk.\n\nThe company initiated a global Phase 2 study for Down Syndrome-associated Alzheimer’s and completed enrollment in a Phase 2 study for Cerebral Amyloid Angiopathy.\n\nAdditionally, Alnylam shared preclinical data and design for the tau-targeting ALN-5288, an asset being developed in collaboration with Regeneron.","key_figures":{"drugName":"Mivelsiran","phaseOfTrial":"Phase 1 and Phase 2","customDimensions":{"global_sites":30,"A_beta_42_reduction":"-70.2%","sAPP_beta_reduction":"-89.9%","treatment_exposure_months":30}},"named_entities":{"people":[{"name":"Toby Ferguson","role":"Senior Vice President and Head of the Neuroscience Therapeutic Area"},{"name":"Michael S. Rafii","role":"Professor of Neurology at the Keck School of Medicine of USC"}],"products":["Mivelsiran","ALN-5288"],"companies":[{"name":"Alnylam Pharmaceuticals, Inc.","ticker":"ALNY"},{"name":"Regeneron Pharmaceuticals","relationship":"collaborator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T07:33:56.327Z","global_importance":35,"audience_relevance":45,"importance_components":{"tickerTier":"mid-large-cap","diseaseArea":"Alzheimer's / Neuroscience","eventGravity":"Phase 1/2 clinical milestones","sectorWeight":"Biotech"}},"durationMs":236116,"modelName":"glm-4.7"}}